Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) (ONC006)
LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Treatment Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients (LUNG CARE Registry)
Sponsor: Myriad Genetic Laboratories, Inc.
Terminated
company decision to terminate
Other terminated trials from Myriad Genetic Laboratories, Inc.
- Primary Invasive Breast Cancer · Mar 2022
- Prostate Cancer · Mar 2022
- Prostate Cancer · Jan 2022
- Lung Adenocarcinoma · Jul 2017
- Colorectal Cancer, Metastatic · Phase PHASE4 · Aug 2012
More terminations from Myriad Genetic Laboratories, Inc.
Other Lung Cancer trials with similar outcome
Listed as NCT02121899, this observational or N/A phase trial focuses on Lung Cancer and NSCLC and remains terminated or withdrawn. Sponsored by Myriad Genetic Laboratories, Inc., it has been updated 11 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 6 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Aug 2017 — Oct 2017 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Myriad Genetic Laboratories, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .